IRF7:系统性硬化症炎症与纤维化的联系
该研究探讨干扰素调节因子7(IRF7)在系统性硬化症(SSc)皮肤纤维化和发病机制中的作用。SSc皮肤组织和成纤维细胞中IRF7表达显著上调并活化;IRF7与Smad3相互作用并增强TGF-β介导的纤维化;IRF7敲除小鼠在博来霉素和TSK/+模型中皮肤纤维化和炎症减轻。结论提示IRF7可能是SSc的潜在治疗靶点。
要点
- SSc皮肤组织和成纤维细胞中IRF7表达显著上调并活化。
- IRF7与Smad3相互作用并增强TGF-β介导的纤维化。
- IRF7敲除在博来霉素和TSK/+小鼠模型中减轻皮肤纤维化和炎症。
核心结论
- IRF7在SSc皮肤中上调,与Smad3相互作用并增强TGF-β介导的纤维化,可能成为SSc有前景的治疗靶点。
研究设计与样本
- 研究比较SSc与健康对照皮肤活检中IRF7表达和活化,并使用IRF7敲除小鼠在博来霉素诱导和TSK/+小鼠模型中研究纤维化作用,同时进行SSc和健康对照皮肤成纤维细胞的体外实验。
主要发现
- 与未受累的匹配对照相比,SSc皮肤组织和移植的SSc真皮成纤维细胞中IRF7表达显著上调并活化。
- IFN-α可刺激真皮成纤维细胞中IRF7表达。
- IRF7与TGF-β信号关键介质Smad3共免疫沉淀,且IRF7敲低减少SSc成纤维细胞中的促纤维化因子。
- 在博来霉素反应中,IRF7敲除小鼠较野生型小鼠皮肤纤维化和炎症减轻,皮肤组织中羟脯氨酸含量、真皮厚度以及Col1a2、ACTA2和白细胞介素-6 mRNA水平显著减弱。
- 在TSK/+小鼠中IRF7敲除减轻羟脯氨酸含量、皮下真皮厚度、Col1a2 mRNA以及α-平滑肌肌动蛋白和纤连蛋白表达。
临床怎么用
- IRF7可能作为SSc纤维化和炎症的潜在治疗靶点,但尚需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There is considerable evidence that implicates dysregulation of type I interferon signalling (or type I IFN signature) in the pathogenesis of systemic sclerosis (SSc). Interferon regulatory factor 7 (IRF7) has been recognised as a master regulator of type I IFN signalling. The objective of this study was to elucidate the role of IRF7 in dermal fibrosis and SSc pathogenesis. METHODS: SSc and healthy control skin biopsies were investigated to determine IRF7 expression and activation. The role of IRF7 in fibrosis was investigated using IRF7 knockout (KO) mice in the bleomycin-induced and TSK/+mouse models. In vitro experiments with dermal fibroblasts from patients with SSc and healthy controls were performed. RESULTS: IRF7 expression was significantly upregulated and activated in SSc skin tissue and explanted SSc dermal fibroblasts compared with unaffected, matched controls. Moreover, IRF7 expression was stimulated by IFN-α in dermal fibroblasts. Importantly, IRF7 co-immunoprecipitated with Smad3, a key mediator of transforming growth factor (TGF)-β signalling, and IRF7 knockdown reduced profibrotic factors in SSc fibroblasts. IRF7 KO mice demonstrated attenuated dermal fibrosis and inflammation compared with wild-type mice in response to bleomycin. Specifically, hydroxyproline content, dermal thickness as well as Col1a2, ACTA2 and interleukin-6 mRNA levels were significantly attenuated in IRF7 KO mice skin tissue. Furthermore, IRF7 KO in TSK/+mice attenuated hydroxyproline content, subcutaneous hypodermal thickness, Col1a2 mRNA as well as α-smooth muscle actin and fibronectin expression. CONCLUSIONS: IRF7 is upregulated in SSc skin, interacts with Smad3 and potentiates TGF-β-mediated fibrosis, and therefore may represent a promising therapeutic target in SSc.
引用
- Wu M, Skaug B, Bi X, et al. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis. Ann Rheum Dis. 2019. PMID: 31439591. doi:10.1136/annrheumdis-2019-215208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。